Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Moderna To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Moderna between January 18, 2023 and June 25, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Sept. 12, 2024 /PRNews ...

文章核心观点 - 公司将精简研发管线,专注于获得10款产品的FDA批准,包括治疗RSV和癌症的疫苗,以及新冠和流感联合疫苗 [1] - 公司预计通过上述举措到2027年将开支降低11亿美元 [1] - 公司预计未来3年内获得10款新产品的FDA批准 [2] - 公司预计2025年收入将在25亿至35亿美元之间,2028年实现现金盈亏平衡,届时收入将达到60亿美元 [3] 公司相关 - 公司将专注于获得10款产品的FDA批准,包括5款呼吸道疾病疫苗和5款癌症及罕见疾病疫苗 [2] - 公司今年研发支出预计为48亿美元,到2027年底将降至36亿至38亿美元 [2] - 公司股价在盘前交易中下跌超过12% [3] 行业相关 无相关内容

文章核心观点 - 公司计划到2027年削减约11亿美元的开支,同时获批多款新产品 [1][2][3] - 公司将暂停部分管线项目,并放缓新的研发投入 [2] - 公司预计2025年收入将达到25-35亿美元,2026-2028年复合年增长率将超过25% [4] - 公司研发成功率是行业平均水平的6倍 [4] 新产品管线 - 公司计划在2027年前获批10款新产品 [1] - 公司有5款呼吸系统疫苗获得三期阳性结果,其中3款将于今年提交申请 [3] - 公司还有5款非呼吸系统产品(癌症、潜伏病毒和罕见疾病)有望在2027年前获批 [3]

NEW YORK, Sept. 12, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Moderna, Inc. (NASDAQ: MRNA). Shareholders who purchased shares of MRNA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/moderna-loss-submission-form/?id=101868&from=4 CLASS PERIOD: January 18, 2023 to June 2 ...

Building on successful pre-clinical in vivo CAR-M data in oncology, the companies will develop in vivo CAR-M for autoimmune diseases Moderna nominated two autoimmune disease targets under the collaboration Carisma is eligible to receive milestones and royalty payments PHILADELPHIA, Sept. 10, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced th ...

NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Moderna, Inc. (NASDAQ: MRNA) between January 18, 2023 and June 25, 2024, both dates inclusive (the "Class Period"), of the important October 8, 2024 lead plaintiff deadline. SO WHAT: If you purchased Moderna securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT T ...

文章核心观点 - 欧洲药品管理局(EMA)的药品评审委员会(CHMP)对Moderna公司针对JN.1变异株的新冠疫苗Spikevax给予了积极意见,建议批准上市[1] - 该疫苗针对6个月及以上人群进行预防新冠疾病的主动免疫[1] - 该疫苗将在2024-2025年度季节上市,需等待欧盟委员会的最终决定[1] - CHMP的决定基于制造和临床前数据,以及之前临床、非临床和实际使用证据支持该疫苗的安全性和有效性[1] 行业相关 - EMA在2024年4月发布指南,建议疫苗制造商针对Omicron JN.1亚变种开发更新的新冠疫苗[2] - 与行业下跌0.9%相比,Moderna公司股价今年迄今下跌26.1%[2] 公司相关 - Spikevax针对JN.1变异株已获得美国、英国、日本和台湾的批准[3] - 美国FDA还批准了Moderna公司针对KP.2毒株的更新疫苗,以及辉瑞/BioNTech公司的更新疫苗[3] - FDA批准了针对12岁及以上人群使用的更新疫苗,并授予6个月至11岁人群使用的低剂量更新疫苗紧急使用授权[3] - FDA在2024年6月建议疫苗制造商开发针对KP.2毒株的更新疫苗,供2024年秋季使用[4] - 由于新冠疫情大幅减弱,疫苗制造商PFE、BNTX和MRNA的产品销售和市值均出现大幅下降,即使最近美国新冠感染有所上升,但收入和利润的大幅增长也不太可能[4]

NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Moderna, Inc. (NASDAQ: MRNA) between January 18, 2023 and June 25, 2024, both dates inclusive (the "Class Period"), of the important October 8, 2024 lead plaintiff deadline. SO WHAT: If you purchased Moderna securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT T ...

NEW YORK , Sept. 5, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Moderna, Inc. (NASDAQ: MRNA). Shareholders who purchased shares of MRNA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/moderna-loss-submission-form/?id=100107&from=4 CLASS PERIOD: January 18, 2023 to June 2 ...

SAN DIEGO, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Moderna, Inc. (NASDAQ: MRNA) securities between January 18, 2023 and June 25, 2024. Moderna is a biotechnology company that discovers, develops, and commercializes messenger RNA ("mRNA") therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular dis ...